%0 Journal Article %J International Journal of Pharmaceutics %D 2010 %T Anti-CD8 conjugated nanoparticles to target mammalian cells expressing CD8 %A Bicho, A. %A Peça, Inês N %A Roque, A. C. A. %A Cardoso, M Margarida %K Animals %K Antibodies %K Antigens %K Cell Culture Techniques %K Cell Line %K Cricetinae %K Cricetulus %K Drug Carriers %K Electron %K Fluorescence %K Fourier Transform Infrared %K Humans %K Lactic Acid %K Microscopy %K Monoclonal %K nanoparticles %K Polyglycolic Acid %K Scanning %K Spectroscopy %K Surface Properties %K Transfection %K Tumor %K {CD8} %K {CHO} Cells %K {Phase-Contrast} %P 80–86 %R 10.1016/j.ijpharm.2010.08.005 %U http://www.ncbi.nlm.nih.gov/pubmed/20696228 %V 399 %X

This work aimed at the development of targeted drug delivery systems using nanoparticles fused with antibodies. The antibody anti-human {CD8} was coupled onto {PLGA} nanoparticles, and the ability of these particles to specifically target cells expressing {CD8} was studied. The obtained particles were found to be of spherical shape exhibiting a size between 350 and 600 nm. In vitro experiments with different cellular cultures {(TE671}, {CHO} and {HEK293)} using unmodified nanoparticles containing rhodamine have shown that particles were present on their surface within 48 h of incubation. In vitro tests using {anti-CD8} conjugated nanoparticles in {CHO} cell cultures indicated that all transfected cells which express {CD8} show these particles on their surface within 1h of incubation. These results demonstrated that, in a shorter time, the produced particles can target cells expressing {CD8} on their surface which offers the ability to reduce drug side effects. The antibody-coupled nanoparticles represent a promising approach to improve the efficacy of active targeting for lymphoblastic leukaemia therapy.


{PMID:} 20696228